The predicament of hypermobility within the temporomandibular joint is associated with pain, notable mouth opening and related degenerative disorders. The review attempts to evaluate the probability of an approach dextrose prolotherapy to alleviate temporomandibular joint hypermobility associated symptoms.

The systematic review aimed to investigate the possible evidence to evaluate the dextrose prolotherapy efficiency in recovering outcomes of temporomandibular joint (TMJ) hypermobility as compared to placebo.

The PubMed, Scopus, CENTRAL and Google scholar databases that published in the English language up to February 2018 were searched. Controlled clinical trials (CCTs) and Randomised clinical trials (RCTs) which made the comparison between dextrose prolotherapy and placebo to manage TMJ hypermobility were introduced.

A total of three RCTs were incorporated in the evaluation. Two trials inscribed the subluxation/dislocation frequency which found with no difference within placebo and dextrose. On pooling of data, a statistically significant difference was noticed in the reduction of MMO with the dextrose prolotherapy use (random: MD = -3.32, 95% CI -5.26 to -1.28; P = 0.0008; I2 = 0%). the dextrose prolotherapy therapy also exhibited a statistically significant difference in pain reduction compared to placebo (random: MD = -1, 95% CI -1.58 to -0.42; P = 0.0007; I2 = 0%).

Inside the constraints of the study, dextrose prolotherapy may present with a meaningful reduction in mouth opening and pain allied with TMJ hypermobility. Findings concerning the reduction of episodes of subluxation/dislocation cannot be drawn. There is a requirement for further high-quality RCTs with larger sample size and homogenous prolotherapy protocol to bring substantial results on the influence of dextrose prolotherapy in patients with TMJ hypermobility.